- Home
- MTCH vs CDTX Comparison
MTCH vs CDTX Comparison
Compare MTCH & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTCH | CDTX |
|---|---|---|
| Founded | 1986 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 6.9B |
| IPO Year | 2015 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MTCH | CDTX |
|---|---|---|
| Price | $32.54 | $220.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 12 |
| Target Price | $35.27 | ★ $128.75 |
| AVG Volume (30 Days) | ★ 3.1M | 960.9K |
| Earning Date | 02-03-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.15 | N/A |
| Revenue | ★ $3,469,367,000.00 | N/A |
| Revenue This Year | $2.06 | N/A |
| Revenue Next Year | $3.38 | N/A |
| P/E Ratio | $15.32 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.39 | $15.22 |
| 52 Week High | $39.20 | $221.20 |
Technical Indicators
Market Signals| Indicator | MTCH | CDTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.79 | 85.79 |
| Support Level | $32.34 | $219.91 |
| Resistance Level | $33.73 | $221.00 |
| Average True Range (ATR) | 0.68 | 0.54 |
| MACD | -0.08 | -3.90 |
| Stochastic Oscillator | 18.36 | 87.86 |
Price Performance
Historical ComparisonAbout MTCH Match Group Inc.
Match Group Inc is a provider of online dating products. The company's portfolio of brands includes Tinder, Hinge, Match, Meetic, OkCupid, Pairs, Plenty Of Fish, Azar, BLK, and more, each built to increase its user's likelihood of connecting with others. The company has four operating segments: Tinder, Hinge, Evergreen and Emerging, and Match Group Asia. The company generates the majority of its revenue from the Tinder segment.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.